Skip to content

AARD - Aardvark Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

Aardvark Therapeutics, Inc. Common Stock

AARD · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

AARDAardvark Therapeutics, Inc. Common Stock

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $17.94
52-wk low: $3.35
Prev close: $10.32
Mkt cap: $147.7M
P/B: 1.8x
Profit margin: +0.0%

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$13.5M

CI
Citadel
Ken Griffin · Q2 2026 13F
$7.4M
position
AQ
AQR
Q2 2026 13F

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $148M

Valuation

P/B1.81

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: AARD
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $147.72M

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Op margin

+0.0%

ROE

-66.0%

$2.8M

position

SC

Schonfeld

Steven Schonfeld · Q4 2025 13F

$658K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for AARD

No recent insider trade
No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

EPS expected

-$0.88

-$1.13 to -$0.58

Revenue expected

$0.00

10 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.01

Change in 30 days

-66.0%

ROA-40.4%

Growth